27 articles for M Asano
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
4
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives.
Takeda Pharmaceutical
3
Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists.
Takeda Pharmaceutical
46
Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxyhexanamides to reduce a cardiac safety issue: discovery of DS-8108b, an orally active renin inhibitor.
Daiichi Sankyo
13
Design and synthesis of potent inhibitor of apoptosis (IAP) proteins antagonists bearing an octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline mimetic.
Takeda Pharmaceutical
25
Synthesis and SAR of 1,3-thiazolyl thiophene and pyridine derivatives as potent, orally active and S1P3-sparing S1P1 agonists.
Daiichi Sankyo
35
A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.
Fujisawa Pharmaceutical
24
Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.
Fujisawa Pharmaceutical
32
A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile.
Fujisawa Pharmaceutical
48
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
Fujisawa Pharmaceutical
22
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.
Fujisawa Pharmaceutical
58
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
Fujisawa Pharmaceutical
38
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.
Fujisawa Pharmaceutical
3
Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.
Daiichi Sankyo
32
Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist.
Daiichi Sankyo
22
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
Daiichi Sankyo Co.
1
Identification of novel benzimidazole derivatives as highly potent AMPK activators with anti-diabetic profiles.
Shionogi
6
Identification of novel indole derivatives as highly potent AMPK activators with anti-diabetic profiles.
Shionogi
12
Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring.
Daiichi Sankyo
1
Discovery of DS34942424: An orally potent analgesic without mu opioid receptor agonist activity.
Daiichi Sankyo
20
Synthesis and biological evaluation of novel imidazol-1-ylacetic acid derivatives as non-brain penetrant bombesin receptor subtype-3 (BRS-3) agonists.
Daiichi Sankyo
5
Discovery of a novel bicyclic compound, DS54360155, as an orally potent analgesic without mu-opioid receptor agonist activity.
Daiichi Sankyo
4
The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitor.
Takeda Pharmaceutical
5
Discovery of conolidine derivative DS39201083 as a potent novel analgesic without mu opioid agonist activity.
Daiichi Sankyo
5
Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Takeda Pharmaceutical
17
Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.
Takeda Pharmaceutical
20
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.
Takeda Pharmaceutical
38
Purine inhibitors of human phosphatidylinositol 3-kinase delta
Merck Sharp & Dohme